Terray Therapeutics, Inc. is making moves.

The Monrovia-based biotech company announced a partnership with Boston-based Odyssey Therapeutics Inc. in late October, just weeks after closing a $120 million series B funding round. 

Terray Therapeutics is the brainchild of brothers Jacob and Eli Berlin. The company launched out of stealth in 2022 to use computational analysis and artificial intelligence to speed up the process of drug discovery. The series B marks the company’s second financing round. It is twice as large as the $60 million series A financing it closed in 2022. 

Terray Therapeutics’ drug discovery platform, called tNova, is an enticing concept for venture firms and pharmaceutical companies alike – due to rigorous federal standards for drugs, it takes around 10 years for the Food and Drug Administration to approve a new drug. In its wake are the other 90% of drugs that failed in some part of the drug development process, each of which cost around $1 billion to make. 

Terray Therapeutics’ drug discovery platform is meant to speed up the process of developing a new drug and, as a result, lowering the cost of producing each one. The company’s platform analyzes different chemical compounds and puts them together in different compositions to analyze which ones will weather various storms – animal testing, clinical trials and a review from the FDA.

“The core technology is a measurement technology that doesn’t prescribe necessarily what you have to do with it,” said Jacob Berlin, cofounder and chief executive at Terray. “And so we have chosen to focus on small molecule drug development for autoimmune disorders and immunology disorders for ourselves.”